Clinical trial
Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating…
NCT00003484 · Darell D. Bigner, MD, PhD, Other · Completed
Key facts
| NCT number | NCT00003484 |
|---|---|
| Title | Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors |
| Official title | Phase I Study of Anti-Tenascin Monoclonal Antibody I-Labeled 81C6 Via Surgically Created Cystic Resection Cavity in the Treatment of Patients With Primary Brain Tumors After External Beam Radiotherapy |
| Lead sponsor | Darell D. Bigner, MD, PhD, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors, Neuroblastoma |
| Intervention type | Drug, Procedure, Radiation |
| Interventions | carmustine, irinotecan hydrochloride, surgical procedure, iodine I 131 monoclonal antibody 81C6 |
| Enrollment | 21 |
| Start date | Sep 1, 1997 |
| Primary completion | Nov 1, 2003 |
| Completion | Mar 1, 2010 |
| First posted | Apr 30, 2003 |
| Last update posted | Apr 23, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: